Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

Official Title

Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

Summary:

The primary aim of the study is to identify genomic and circulating tumour cell (CTC) markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic and CTC markers to evaluate metastatic risk in breast cancer following primary treatments.

Trial Description

Primary Outcome:

• Pathologic complete response (pCR)

Secondary Outcome:

• Time to distant breast cancer recurrence (months)
• Time to distant metastasis
• Time to death

The study aims to evaluate genetic and CTC markers in breast tumours to predict therapy response and metastatic risk.

View this trial on ClinicalTrials.gov